Literature DB >> 10219926

Burden of migraine in the United States: disability and economic costs.

X H Hu1, L E Markson, R B Lipton, W F Stewart, M L Berger.   

Abstract

BACKGROUND: Migraine is a common disabling disease but its economic burden has not been adequately quantified.
OBJECTIVE: To estimate the burden of migraine in the United States with respect to disability and economic costs.
METHODS: The following data sources were used: published data, the Baltimore County Migraine Study, MEDSTAT's MarketScan medical claims data set, and statistics from the Census Bureau and the Bureau of Labor Statistics. Disability was expressed as bedridden days. Charges for migraine-related treatment were used as direct cost inputs. The human capital approach was used in the estimation of indirect costs.
RESULTS: Migraineurs required 3.8 bed rest days for men and 5.6 days for women each year, resulting in a total of 112 million bedridden days. Migraine costs American employers about $13 billion a year because of missed workdays and impaired work function; close to $8 billion was directly due to missed workdays. Patients of both sexes aged 30 to 49 years incurred higher indirect costs compared with younger or older employed patients. Annual direct medical costs for migraine care were about $1 billion and about $100 was spent per diagnosed patient. Physician office visits accounted for about 60% of all costs; in contrast, emergency department visits contributed less than 1% of the direct costs.
CONCLUSIONS: The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. Various screening and treatment regimens should be evaluated to identify opportunities to reduce the disease burden.

Entities:  

Mesh:

Year:  1999        PMID: 10219926     DOI: 10.1001/archinte.159.8.813

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  178 in total

Review 1.  The increasing necessity for market-based pharmaceutical prices.

Authors:  J E Calfee
Journal:  Pharmacoeconomics       Date:  2000       Impact factor: 4.981

Review 2.  Ibuprofen with or without an antiemetic for acute migraine headaches in adults.

Authors:  Roy Rabbie; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 3.  Safety of sumatriptan in pregnancy: a review of the data so far.

Authors:  Elizabeth Loder
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

5.  Validation of the work and health interview.

Authors:  Walter F Stewart; Judith A Ricci; Carol Leotta; Elsbeth Chee
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  The impact of anaemia and its treatment on employee disability and medical costs.

Authors:  Ernst Berndt; William Crown; Joel Kallich; Stacey Long; Xue Song; Gary H Lyman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  The medical care utilization and costs associated with migraine headache.

Authors:  Jennifer Elston Lafata; Christina Moon; Carol Leotta; Ken Kolodner; Laila Poisson; Richard B Lipton
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

Review 9.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

10.  Population-based study of migraine in Spanish adults: relation to socio-demographic factors, lifestyle and co-morbidity with other conditions.

Authors:  César Fernández-de-Las-Peñas; Valentín Hernández-Barrera; Pilar Carrasco-Garrido; Cristina Alonso-Blanco; Domingo Palacios-Ceña; Silvia Jiménez-Sánchez; Rodrigo Jiménez-García
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.